-
Views
-
Cite
Cite
Matthew A Cavender, Stephen J Nicholls, Lincoff A. Michael, Strategies for the development of new PPAR agonists in diabetes, European journal of cardiovascular prevention and rehabilitation, Volume 17, Issue 1_suppl, 1 May 2010, Pages s32–s37, https://doi.org/10.1097/01.hjr.0000368196.17109.5e
- Share Icon Share
Abstract
Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed. Eur J Cardiovasc Prev Rehabil 17 (Suppl 1):S32-S37 ©2010 The European Society of Cardiology
Comments